## AMENDMENTS TO THE CLAIMS

**1. (Currently Amended)** A method for treating amyotrophic lateral sclerosis or symptoms caused by amyotrophic lateral sclerosis and/or suppressing the progression thereof, which comprises administering to a patient in need thereof as an active ingredient 3-methyl-1-phenyl-2-pyrazoline-5-one, or a physiologically acceptable salt thereof, ~~or a hydrate thereof,~~ under the condition that a combination of a drug administration period of ~~1 day to about~~ 14 days and a drug holiday period of ~~1 day to about~~ 14 days is repeated during the period for treating the disease or suppressing the progression of the disease.

**2-6. (Cancelled)**

**7. (Currently Amended)** ~~The method of claim 1, wherein~~ A method for treating amyotrophic lateral sclerosis or symptoms caused by amyotrophic lateral sclerosis and/or suppressing the progression thereof, which comprises administering to a patient in need thereof as an active ingredient 3-methyl-1-phenyl-2-pyrazoline-5-one or a physiologically acceptable salt thereof, under the condition that a course consisting of an initial drug administration period of 14 days and a drug holiday period of 14 days is provided, followed by repetitions of the following combination of periods:

drug administration period: 5 days per week for 2 weeks; and

drug holiday period: 14 days.

**8. (Currently Amended)** The method of claim 1, wherein the daily dose contains about 15 to 240 mg of 3-methyl-1-phenyl-2-pyrazoline-5-one ~~as an active ingredient, or about 15 to 240 mg of 3-methyl-1-phenyl-2-pyrazoline-5-one contained in a pharmaceutically acceptable salt of 3-methyl-1-phenyl-2-pyrazoline-5-one or a hydrate of 3-methyl-1-phenyl-2-pyrazoline-5-one~~ or a pharmaceutically acceptable salt thereof as an active ingredient.

**9. (Currently Amended)** The method of claim 1, wherein the daily dose contains about 60 mg of 3-methyl-1-phenyl-2-pyrazoline-5-one ~~as an active ingredient, or about 60 mg of 3-methyl-1-phenyl-2-pyrazoline-5-one contained in a pharmaceutically acceptable salt of 3-methyl-1-phenyl-2-pyrazoline-5-one or a hydrate of 3-methyl-1-phenyl-2-pyrazoline-5-one~~ or a pharmaceutically acceptable salt thereof as an active ingredient.

**10. (Previously Presented)** The method of claim 1, wherein the administration is carried out once daily.

**11. (Previously Presented)** The method of claim 1, wherein the administration is a continuous administration.

**12. (Previously Presented)** The method of claim 11, wherein the continuous administration is intravenous infusion administration.

**13. (Currently Amended)** The method of claim 12, wherein the administration rate in the intravenous infusion administration is about 0.5 to 1 mg/minute with respect to 3-methyl-1-phenyl-2-pyrazoline-5-one as an active ingredient~~ or 3-methyl-1-phenyl-2-pyrazoline-5-one contained in an active ingredient~~.

**14. (Cancelled)**

**15. (Previously Presented)** The method of claim 1, wherein the symptoms caused by amyotrophic lateral sclerosis are decreased respiratory function, voice and speech disorders, dysphagia, or upper and lower extremity motor disorders.

**16. (Previously Presented)** The method of claim 1, wherein the treatment of amyotrophic lateral sclerosis or symptoms caused by amyotrophic lateral sclerosis and/or the suppression of the progression thereof is a suppression of decrease in respiratory function in amyotrophic lateral sclerosis.

**17-32. (Cancelled)**

**33. (New)** The method of claim 7, wherein the daily dose contains about 15 to 240 mg of 3-methyl-1-phenyl-2-pyrazoline-5-one or a pharmaceutically acceptable salt thereof as an active ingredient.

**34. (New)** The method of claim 7, wherein the daily dose contains about 60 mg of 3-methyl-1-phenyl-2-pyrazoline-5-one or a pharmaceutically acceptable salt thereof as an active ingredient.

**35. (New)** The method of claim 7, wherein the administration is carried out once daily.

**36. (New)** The method of claim 7, wherein the administration is a continuous administration.

**37. (New)** The method of claim 36, wherein the continuous administration is intravenous infusion administration.

**38. (New)** The method of claim 37, wherein the administration rate in the intravenous infusion administration is about 0.5 to 1 mg/minute with respect to 3-methyl-1-phenyl-2-pyrazoline-5-one as an active ingredient.

**39. (New)** The method of claim 7, wherein the symptoms caused by amyotrophic lateral sclerosis are decreased respiratory function, voice and speech disorders, dysphagia, or upper and lower extremity motor disorders.

**40. (New)** The method of claim 7, wherein the treatment of amyotrophic lateral sclerosis or symptoms caused by amyotrophic lateral sclerosis and/or the suppression of the progression thereof is a suppression of decrease in respiratory function in amyotrophic lateral sclerosis.